Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease

Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study

(2018) Bella Ungar et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease

(2018) Kenji Watanabe et al.   Clinical Gastroenterology and Hepatology

Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease

(2018) Anna Juncadella et al.   DIGESTIVE DISEASES AND SCIENCES

Therapeutic Drug Monitoring Guides the Management of Crohn’s Patients with Secondary Loss of Response to Adalimumab

(2018) Sophie Restellini et al.   INFLAMMATORY BOWEL DISEASES

OP031 Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study

(2018) N A Kennedy et al.   Journal of Crohns & Colitis

Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study

(2018) Luisa Guidi et al.   Journal of Crohns & Colitis

Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease

(2018) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing

(2018) Bram Verstockt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

(2017) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2016) Bella Ungar et al.   Clinical Gastroenterology and Hepatology

Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results

(2016) Gil Y. Melmed et al.   Clinical Gastroenterology and Hepatology

Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis

(2016) Andres J. Yarur et al.   INFLAMMATORY BOWEL DISEASES

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis

(2016) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn’s Disease

(2016) E. Zittan et al.   Journal of Crohns & Colitis

Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease

(2016) Yukihiro Morita et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis

(2016) Yukihiro Morita et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

(2015) Henit Yanai et al.   Clinical Gastroenterology and Hepatology

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Xavier Roblin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease

(2014) Byron P. Vaughn et al.   INFLAMMATORY BOWEL DISEASES

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab

(2013) Fernando S. Velayos et al.   Clinical Gastroenterology and Hepatology

Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease

(2013) Mark T. Osterman et al.   Clinical Gastroenterology and Hepatology

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2013) Xavier Roblin et al.   Clinical Gastroenterology and Hepatology

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS